cbdMD (YCBD) Q3 FY26 earnings call

cbdMD achieved significant top-line growth in Q3 FY26, driven by its wholesale channel and the Bluebird acquisition, despite a challenging regulatory landscape. The company made strategic investments and incurred one-time costs, leading to a wider operating loss, but adjusted EBITDA narrowed. Management is proactively addressing regulatory uncertainty with new product launches and cost reductions, aiming for improved profitability and market share in a dynamic environment.